NCT06206785

Resting Energy Expenditure in Palliative Cancer Patients (REPAT) - an Explorative Study in Patients With Incurable Cancer

Extracted Fields (from Registry)
Protocol IDNCT06206785
Registration Date2024-01-16
Statusrecruiting
SponsorNorwegian University of Science and Technology
CountryNorway
Industrynot industry
Blindingunblinded
Center Typesingel-center RCT
Scopenational RCT
First Patient In2023-09-05
Last Patient Out2027-12-31
Publicationn
Gender %ALL
Mean Age18 Years -
LLM Classifications (Side-by-Side)
Field CLAUDE
claude-sonnet-4-20250514
7227ms / 9575 tok
OPENAI
gpt-4o
4489ms / 8235 tok
GLM
glm-5.1
9540ms / 8379 tok
Review
rct_type N/A N/A N/A OK
cancer_status Cancer Cancer Cancer OK
non_cancer_spec N/A N/A N/A OK
setting_patient inpatient inpatient inpatient OK
setting_place hospital hospital hospital OK
feasibility N/A N/A N/A OK
intervention_pharmacologic no no no OK
intervention_chemo_immuno_radio no no no OK
intervention_complementary no no no OK
intervention_device no no no OK
intervention_psychological no no no OK
intervention_complex no no no OK
intervention_acp no no no OK
intervention_music no no no OK
intervention_screening no no no OK
intervention_palliative no no no OK
intervention_education no no no OK
intervention_digital no no no OK
intervention_other no no no OK
outcome_symptom yes yes yes OK
outcome_qol no no no OK
outcome_dignity no no no OK
outcome_cost no no no OK
outcome_other yes yes → yes
shaky reasoning
✓ Unanimous Initial: yes Requery: yes — The study measures survival time (days after REE measurement) as a secondary outcome, which falls outside the symptom/QoL/dignity/cost categories.
yes no → yes
shaky reasoning
✓ Unanimous Initial: no Requery: yes — The trial includes survival as a secondary outcome, which is not covered by symptom/QoL/dignity/cost categories.
yes yes → yes
shaky reasoning
✓ Unanimous Initial: yes Requery: yes — The trial explicitly lists 'survival (days after REE measurement)' as a secondary outcome, which is classified as an 'other' outcome outside the symptom/QoL/dignity/cost categories.
OK
pharmacologic_sub N/A N/A N/A OK
Back to Studies